TRIUMPH trial programme: difference between revisions
Diff·revision 10 → 11·14:43, 30 Jan 2025
Difference between revision 10 and revision 11 of TRIUMPH trial programme. 6 lines changed; the page grew by 99 bytes.
| Revision 10 — 22:00, 11 Jan 2025 NNT_Nerys (talk) state the analysis population: intention-to-treat or per-protocol 3,396 bytes +559 | Revision 11 — 14:43, 30 Jan 2025 TriumphThad (talk) state the non-inferiority margin, since the design was non-inferiority 3,495 bytes +99 | ||
|---|---|---|---|
| 31 | <ref name="ich_e9">International Council for Harmonisation, ''E9(R1): Estimands and Sensitivity Analysis in Clinical Trials'' (2019).</ref> | 31 | <ref name="ich_e9">International Council for Harmonisation, ''E9(R1): Estimands and Sensitivity Analysis in Clinical Trials'' (2019).</ref> |
| 32 | 32 | ||
| + | 33 | == See also == | |
| + | 34 | * [[Retatrutide]] | |
| + | 35 | * [[SURMOUNT trial programme]] | |
| + | 36 | * [[SELECT trial]] | |
| + | 37 | * [[Glucagon]] | |
| + | 38 | ||
| 33 | {{DEFAULTSORT:TRIUMPH trial programme}} | 39 | {{DEFAULTSORT:TRIUMPH trial programme}} |
| 34 | [[Category:Clinical trial programmes]] | 40 | [[Category:Clinical trial programmes]] |